CN60 - Dynamics and processes in the perception of colorectal cancer patients facing skin toxicity due to an EGFR-inhibitor

Background

Epidermal growth factor receptor inhibitors (EGFR-I), such as cetuximab and panitumumab, are treatments that are frequently used in patients with metastatic colorectal cancer. An important side effect of these treatments is skin toxicity, which has a negative impact on patients’ quality of life. The aim of this study is to explore the dynamics and processes in the perception of colorectal cancer patients facing skin toxicity due to an EGFR-I.

Methods

An exploratory qualitative study was conducted, based on the principles of grounded theory. Fifteen semi-structured interviews were performed within two settings, namely a university hospital and a general hospital. The data were analyzed in a cyclical process through thematic analysis and investigator triangulation. For the main themes data saturation was achieved.

Results

The dynamics and processes of the perception of skin toxicity were situated in three impact areas. First, patients described an impact on themselves due to the confrontation with symptoms and a lower self-esteem due to feelings of shame and insecurity caused by the visibility of skin toxicity. This also affected their self-management and the ability to cope with the toxicity. Second, patients outlined an impact of others. For example, comments caused insecurity and the need to hide their skin toxicity or isolate themselves. Additionally, their relatives had to support them in treating the skin toxicity, or skin toxicity sometimes led to an inability to work. Finally, patients stated that healthcare professionals provided emotional support and helped their coping process. In contrast, negative comments of others or from health care professionals could lead to insecurity or frustration.

Conclusions

The side effect of skin toxicity not only has a physical impact but also affects the psychological and social aspects of a colorectal cancer patient's well-being. The digestive oncologist, dermatologist and nurse specialist should take this into account when counselling these patients. Additionally, there is a lack of knowledge about the impact of this side effect by healthcare professionals.

Clinical trial identification

THE-2022-0147.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.